Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAbrdn Di&g Regulatory News (ADIG)

  • This share is currently suspended. It was suspended at a price of 13.33

Share Price Information for Abrdn Di&g (ADIG)

Share Price is delayed by 15 minutes
Get Live Data
13.33    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £40.16m
ADIG Live PriceLast checked at - London Stock Exchange

Intraday Abrdn Di&g Share Chart

Update on Managed Wind-Down

11 Mar 2026 07:00

RNS Number : 1273W
abrdn Diversified Income and Growth
11 March 2026
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED ("UK MAR"). ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THE JURISDICTION.

11 March 2026

For Immediate Release

ABRDN DIVERSIFIED INCOME AND GROWTH PLC

(the "Company")

 

Update on Managed Wind-Down

The Board is pleased to announce that the Company has completed two further secondary sales of its fund investments and private market assets ("Fund Interests") (the "Newly Completed Sales") raising gross consideration of approximately £13.8 million. In addition, the Company has entered into further conditional sale and purchase agreements in respect of an additional Fund Interest (the "Newly Agreed Sale") for gross consideration of approximately £13.3 million (subject to customary completion adjustments and before transaction costs).

As previously reported, each of the Fund Interests sold pursuant to the Newly Completed Sales were being carried by the Company at the agreed sale price in the Company's last reported net asset value ("NAV") (as at 31 December 2025), which also included accruals for the Company's expected transaction, operating and liquidation costs. Furthermore, in the light of the advanced stage of negotiations, the Fund Interest to be sold pursuant to the Newly Agreed Sale was also being carried by the Company at the agreed sale price in the 31 December 2025 NAV.

These recent developments leave only the Fund Interest that is the subject of the Newly Agreed Sale and the remaining 50 per cent. of an additional Fund Interest subject to the Company's secondary sales process (together, the "Remaining Sales").(1) Both of the Remaining Sales are now subject to signed conditional sale agreements. The completion of the Remaining Sales remains subject to certain conditions but are currently expected to complete during the week commencing 16 March 2026. Accordingly, the Board expects to write to shareholders of the Company shortly regarding proposals to place the Company into members' voluntary liquidation. 

The timing of receipt of consideration from the Remaining Sales will be driven by the closing date of the transaction.

Enquiries:

abrdn Diversified Income and Growth plc

Davina Walter (Chairman) via Burson Buchanan

Dickson Minto Advisers LLP

Douglas Armstrong / Andrew Clark / Jamie Seedhouse +44 (0)20 7649 6823

Burson Buchanan

Helen Tarbet / Henry Wilson / Nick Croysdill +44 (0)20 7466 5000

ADIG@buchanancomms.co.uk

Notes:

(1) The Company's interests in Aberdeen Global Private Markets Fund (which was exited through the fund's redemption mechanics in September 2025) and PIMCO Private Income Fund (which is expected to be exited through the fund's redemption mechanics in Q4 2026) were excluded from the Company's secondary sales process. The Company's residual interests in Markel Catco Reinsurance Opportunities Fund (a de minimis holding in a fund in managed wind-down) and Aberdeen European Residential Opportunities Fund (the value of which was written down to nil on 31 January 2025) were also excluded from the Secondary Sales Process.

Important information

This announcement is released by the Company and the information contained within this announcement is deemed by the Company to constitute inside information for the purposes of Article 7 of UK MAR. Upon publication of this announcement via a Regulatory Information Service, such information is now considered to be in the public domain. The person responsible for arranging for the release of this announcement on behalf of the Company is abrdn Holdings Limited, the Company Secretary.

The Company's LEI number is 2138003QINEGCHYGW702.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDBGDXSGBDGLG
Date   Source Headline
23rd Oct 202311:38 amRNSNet Asset Value(s)
20th Oct 20232:38 pmRNSDirector/PDMR Shareholding
20th Oct 202311:56 amRNSNet Asset Value(s)
19th Oct 202312:06 pmRNSNet Asset Value(s)
18th Oct 202312:00 pmRNSNet Asset Value(s)
17th Oct 202311:12 amRNSNet Asset Value(s)
16th Oct 20232:27 pmRNSGearing disclosure
16th Oct 20231:11 pmRNSNet Asset Value(s)
13th Oct 20235:12 pmRNSPortfolio disclosure
13th Oct 202311:42 amRNSNet Asset Value(s)
12th Oct 202311:47 amRNSNet Asset Value(s)
11th Oct 202311:38 amRNSNet Asset Value(s)
10th Oct 202312:56 pmRNSNet Asset Value(s)
9th Oct 20232:41 pmRNSGearing disclosure
9th Oct 20231:36 pmRNSNet Asset Value(s)
6th Oct 202312:34 pmRNSNet Asset Value(s)
5th Oct 20233:23 pmRNSMonth End Net Asset Value(s)
5th Oct 202312:55 pmRNSNet Asset Value(s)
4th Oct 202312:59 pmRNSNet Asset Value(s)
4th Oct 202311:23 amRNSGearing disclosure
3rd Oct 20234:10 pmRNSQuarterly disclosure
3rd Oct 202312:43 pmRNSNet Asset Value(s)
2nd Oct 202310:40 amRNSTotal Voting Rights
29th Sep 20237:00 amRNSCancellation of Treasury Shares
28th Sep 20231:13 pmRNSNet Asset Value(s)
27th Sep 202312:09 pmRNSNet Asset Value(s)
26th Sep 202312:24 pmRNSNet Asset Value(s)
25th Sep 20232:51 pmRNSGearing disclosure
25th Sep 202312:46 pmRNSNet Asset Value(s)
22nd Sep 202312:59 pmRNSNet Asset Value(s)
21st Sep 202312:30 pmRNSNet Asset Value(s)
20th Sep 202312:41 pmRNSNet Asset Value(s)
19th Sep 202312:59 pmRNSNet Asset Value(s)
18th Sep 20231:21 pmRNSGearing Disclosures
18th Sep 202312:27 pmRNSNet Asset Value(s)
15th Sep 202312:21 pmRNSNet Asset Value(s)
14th Sep 20235:32 pmRNSPortfolio Disclosures
14th Sep 202312:40 pmRNSNet Asset Value(s)
13th Sep 20233:09 pmRNSThird Interim Dividend
13th Sep 202312:06 pmRNSNet Asset Value(s)
12th Sep 202312:28 pmRNSNet Asset Value(s)
11th Sep 20231:19 pmRNSGearing disclosure
11th Sep 202312:42 pmRNSNet Asset Value(s)
8th Sep 202312:44 pmRNSNet Asset Value(s)
7th Sep 202312:15 pmRNSNet Asset Value(s)
7th Sep 202310:01 amRNSMonth End Net Asset Value(s)
5th Sep 202311:31 amRNSNet Asset Value(s)
4th Sep 20231:38 pmRNSGearing Disclosures
4th Sep 202312:41 pmRNSNet Asset Value(s)
31st Aug 20231:13 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.